Skip to main content

Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery

Completed · Not applicable · NCT02793492

Conditions: Iliac Artery Stenosis

At a glance

Research payments reported, 2025
$117,035
U.S. investigators named
8
Sites paid
8
Planned or actual enrollment
75

About the trial

Sponsor
Terumo Medical Corporation
Tested
Misago® RX Self-expanding Peripheral Stent (device)
Dates
Started 2022-08-30; completion 2026-07-01
Results posted
Not yet

This is a multi-center, single arm, non-randomized, prospective clinical study using the Misago® RX Self-expanding Peripheral Stent for treatment of de novo, restenotic, and/or occlusive lesion(s) of the common and/or external iliac artery.

From ClinicalTrials.gov, last updated 2026-07-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Terumo Medical Corporation reported $117,035 in research payments for this study in 2025 (48 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Baylor Research Institute $58,487
  • First Coast Cardiovascular Institute PA $27,807
  • University of Florida $9,451
  • Clinre Inc $8,649
  • Novant Health Huntersville Medical Center, NC $4,043
  • Cis Clinical Research Corporation $3,881
  • Holy Name Medical Center Inc $2,396
  • The Christ Hospital Lindner Research Center $2,321

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.